Cancer proteome-expression database: Genome Medicine Database of Japan Proteomics

Abstract

The use of proteome-expression databases may facilitate cancer research. Proteome-expression data derived from a sufficient number of clinical cases may help establish the molecular background of malignant tumors. Recently, we published a proteome expression database, the Genome Medicine Database of Japan (GeMDBJ) Proteomics. The GeMDBJ Proteomics includes the proteome data of surgically resected tissues and tissue-cultured cells of various malignancies, as well as the corresponding biological and clinicopathological data. The proteome data in GeMDBJ Proteomics include expression data produced using 2D PAGE with the immobilized pH gradient gel and DIGE technology, and the protein identification data by liquid chromatography tandem mass spectrometry. GeMDBJ Proteomics can be freely accessed online without registration.

Keywords::

• 2D DIGE
• cancer
• Genome Medicine Database of Japan Proteomics
• mass spectrometry

Acknowledgements

The contributions by Yuki Ishida (GE Healthcare Biosciences) for the PubMed database searching, and Sayaka Miyata (Mitsui Knowledge Industry Ltd) for the monitor of accession to the database are highly appreciated.

Financial & competing interests disclosure

The Genome Medicine Database of Japan Proteomics project is supported by the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation of Japan. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.